Refine
Has Fulltext
- yes (13) (remove)
Is part of the Bibliography
- yes (13)
Year of publication
- 2018 (13) (remove)
Document Type
- Journal article (8)
- Preprint (3)
- Conference Proceeding (2)
Language
- English (13)
Keywords
- PET (7)
- Positronen-Emissions-Tomografie (7)
- neuroendocrine tumor (5)
- 18F-DCFPyL (3)
- DaTscan (3)
- SPECT (3)
- theranostics (3)
- Ioflupane (2)
- PET/CT (2)
- PRRT (2)
- PSMA-PET (2)
- Parkinson (2)
- Parkinson Disease (2)
- Parkinson-Krankheit (2)
- Positron Emission Tomography (2)
- Prostate Cancer (2)
- RADS (2)
- SSTR (2)
- Virchow Node (2)
- [177Lu]-DOTATATE/-DOTATOC (2)
- [68Ga] (2)
- molecular imaging (2)
- personalized medicine (2)
- positron emission tomography (2)
- prostate cancer (2)
- somatostatin receptor (2)
- tumor heterogeneity (2)
- 123I-Ioflupane (1)
- 18F-FDG (1)
- 2-deoxy-2-(18F)fluoro-D-glucose (1)
- PSMA (1)
- PSMA-RADS (1)
- Pancreas (1)
- Parkinsonism (1)
- Parkinson’s disease (1)
- SPECT/CT (1)
- SSTR-PET (1)
- Single-Photon-Emissions-Computertomographie (1)
- TKI (1)
- [68Ga]DOTATOC (1)
- ageing (1)
- interobserver (1)
- interreader (1)
- medullary thyroid carcinoma (1)
- pancreas (1)
- peptide receptor (1)
- peptide receptor radionuclide therapy (1)
- prostate-specific membrane antigen (PSMA) (1)
- quantification (1)
- radionuclide therapy (1)
- reporting and data system (1)
- reporting and data systems (1)
- sarcoidosis (1)
- somatostatin receptor (SSTR) (1)
- somatostatin receptors (1)
- standardization (1)
- tyrosine kinase inhibitor (1)
- vandetanib (1)
Institute
- Klinik und Poliklinik für Nuklearmedizin (13) (remove)
Sonstige beteiligte Institutionen
EU-Project number / Contract (GA) number
- 701983 (12)
Sarcoidosis is a multisystem granulomatous disorder of unknown etiology that can involve virtually all organ systems. Whereas most patients present without symptoms, progressive and disabling organ failure can occur in up to 10% of subjects. Somatostatin receptor (SSTR)-directed peptide receptor radionuclide therapy (PRRT) has recently received market authorization for treatment of SSTR-positive neuroendocrine tumors.
Methods:
We describe the first case series comprising two patients with refractory multi-organ involvement of sarcoidosis who received 4 cycles of PRRT.
Results:
PRRT was well-tolerated without any acute adverse effects. No relevant toxicities could be recorded during follow-up. Therapy resulted in partial response accompanied by a pronounced reduction in pain (patient #1) and stable disease regarding morphology as well as disease activity (patient #2), respectively.
Conclusion:
Peptide receptor radionuclide therapy in sarcoidosis is feasible and might be a new valuable tool in patients with otherwise treatment-refractory disease. Given the long experience with and good tolerability of PRRT, further evaluation of this new treatment option for otherwise treatment-refractory sarcoidosis in larger patient cohorts is warranted.